Central Nervous System Drug Delivery Market - Forecast(2022 - 2027)

Report Code: HCR 1415 Report Format: PDF + Excel

Central Nervous System Drug Delivery Market Overview

Central Nervous System Drug Delivery market size was valued at $ 1,538 million in 2020, and is anticipated to grow at a CAGR of 4.1% during the forecast period 2021-2026. The brain is a highly sensitive and fragile neuronal organ system that needs a regular supply of fuels, gases, and nutrients to maintain homeostasis and other vital functions. But blood-brain barrier a vasculature of the central nervous system acts as a physical barrier and imposes various obstacles. It inhibits the delivery of biological therapies agents to the CNS and imposes obstruction for delivery of a large number of drugs, including antibiotics, antineoplastic agents, and neuropeptides, to pass through the endothelial capillaries to brain. Though several drug delivery methods and strategies have been developed for CNS related disease therapeutics, most of them are proved invasive and lack the target specificity as all traditional drug delivery methods are based on trials and errors. Apart from this, maintaining normal body functions and transport of various biological therapeutic agents across biological membranes is highly essential. However, only few of the existing methods allow drugs for suitable and successful membrane permeation. Moreover, new drug delivery methods are developed based on rational drug design and using high throughput screening receptor-ligand interactions to find appropriateness of the drug among thousands of new compounds. All these factors are to boost the CNS drug delivery industry in the forecast period 2021-2026. However, governments in both developed and developing countries are encouraging cost-saving measures which is affecting the profitability of several pharmaceutical companies which is poised to hinder the Central Nervous System Drug Delivery market growth.

Report Coverage

The report: “Central Nervous System Drug Delivery Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis of the following segments of the Central Nervous System Drug Delivery Market:
By Disease Type: Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer and Others.
By Drug Delivery System: Non-Invasive Methods and Invasive Methods.
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies and Others.
By Geography: North America (U.S, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Russia and Others), APAC (China, Japan, India, South Korea, Australia and Others), South America(Brazil, Argentina and Others) and RoW(Middle East and Africa).

Key Takeaways

  • Geographically, North America region held the highest market share of 35.34% in 2020. 
  • The factors such as the increasing consumer awareness regarding such drug delivery coupled with rising prevalence of biological therapies are amongst the major factor projected to impel growth of Central Nervous System Drug Delivery market.
  • Additionally, factors such as companies investing in novel innovations to improvise and evaluate their product portfolio through technological up gradations thereby, obtaining varying stability and dispensability at all levels are to create opportunities paving a way for the growth in the market during forecast period 2021-2026.

Central Nervous System Drug Delivery Market Segment Analysis – By Distribution Channel, 2020(%)
Central Nervous System Drug Delivery Market Segment Analysis
For More Details on This Report - Request for Sample

Central Nervous System Drug Delivery Market Segment Analysis - By Disease Type

On the basis of disease type, neurodegenerative disease segment accounted for the largest segmental revenue of the Central Nervous System Drug Delivery market in 2020. The large share can be attributed to the fact that the neurodegenerative disease is a key CNS disease which consists of multiple sclerosis, Alzheimer’s disease, and Parkinson’s disease and there is growing incidence for the treatment of such diseases which increases in the adoption of various drug delivery system for these disease thereby, accelerating the growth of the Central Nervous System Drug Delivery market. Furthermore, this segment is projected to dominate over the forecast period 2021-2026 with a CAGR of 4.3% as most of the consumers who are opting for treatment of such diseases are of high costs but strong pipeline products are underway which are also aiding further increase in the growth of this market.

Central Nervous System Drug Delivery Market Segment Analysis - By Distribution Channel

In 2020, on the basis of distribution channel, hospital pharmacies segment accounted for the largest segmental revenue of the Central Nervous System Drug Delivery market on account of the notable number of inpatient and outpatient visiting to hospitals followed by the requirement of large volumes of such drug delivery and their respective drugs are to cater the market revenue for the segment.

On the contrary, retail pharmacies segment is projected to witness healthy growth throughout the forecast period 2021-2026 with a CAGR of 4.6% since there is an increasing access to the prescription drug deliveries followed by their respective discounts provided. Apart from this, owing to the customer flexibility many retail outlets are also starting to invest in such products which is also set to increase the growth of the market during the forecast period 2021-2026.

Central Nervous System Drug Delivery Market Segment Analysis - By Geography

North America is the major region dominating the Central Nervous System Drug Delivery market with a market share of 35.34% in the year 2020. This can be attributed to rising awareness of health and the growing pharmaceutical industry. Moreover, increasing neurodegenerative diseases are rising the demand for Central Nervous System Drug Delivery market. Apart from this, U.S. is the largest producer of Central Nervous System Drug Delivery in the North American market, also the country has expanded its domestic market during recent years mainly owing to its growing pharmaceutical market players market across the region.

On the other hand, Asia Pacific is projected to be the significant-growing market during the forecast period 2021-2026 owing to the emergence of pharmaceutical industry during the forecast period 2021-2026. Furthermore, increasing awareness regarding mental health and initiatives of the government and non-profit organizations in countries like China and India are paving the way for demand hence, increasing the growth of the market in Asia Pacific region.

Central Nervous System Drug Delivery Market Drivers

Rising Adoption of Novel Technologies

The Central Nervous System Drug Delivery market driver can be attributed to the increasing demand for the adoption of modern systems which increases the use of novel Central Nervous System Drug Delivery that contributing to the growth of Central Nervous System treatments. Furthermore, there is an increase in the prevalence of various chronic diseases followed by its digitalization are also increasing the market growth of Central Nervous System Drug Delivery market.

Central Nervous System Drug Delivery Market Challenges

Pressure in Pricing Surge Down

The restraining factor that is to create a negative impact during the forecast period 2021-2026 is the increasing pressure for pricing surge down as governments in both developed and developing countries are encouraging cost-saving measures which is affecting the profitability of several pharmaceutical companies.

Central Nervous System Drug Delivery Market Landscape

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Central Nervous System Drug Delivery market. In 2020, Central Nervous System Drug Delivery market share is fragmented by the top ten players present in the market. The Central Nervous System Drug Delivery market top 10 companies are Angiochem, D-Pharm, Biogen Inc, Otsuka Pharmaceutical Co. Ltd, Eli Lilly and Company, Merck & Co., AstraZeneca, Takeda Pharmaceutical Company Limited, Flowonix Medical, Lauren Sciences and others.

Relevant Reports:

Report Code: HCR 0699 
Report Code: HCR 0217

For more Lifesciences and Healthcare related reports, please click here
1. Central Nervous System Drug Delivery Market - Overview
    1.1 Definitions and Scope
2. Central Nervous System Drug Delivery Market - Executive Summary
    2.1 Market Revenue and Key Trends by Company
    2.2 Key trends by Disease Type
    2.3 Key trends by Distribution Channel
    2.4 Key trends by Geography
3. Central Nervous System Drug Delivery Market – Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split by Key Companies
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis
4. Central Nervous System Drug Delivery Market - Startup Companies Scenario Premium
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Central Nervous System Drug Delivery Market – Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Central Nervous System Drug Delivery Market Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Central Nervous System Drug Delivery Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Central Nervous System Drug Delivery Market – By Disease Type (Market Size -$Million/$Billion)
    8.1 Neurovascular Diseases
    8.2 CNS Trauma
    8.3 Mental Health
        8.3.1 Anxiety Disorders
        8.3.2 Epilepsy
        8.3.3 Mood Disorders
        8.3.4 Psychotic Disorders
        8.3.5 Others
    8.4 Neurodegenerative Diseases
        8.4.1 Alzheimer's Disease
        8.4.2 Parkinson’s Disease
        8.4.3 Multiple Sclerosis
        8.4.4 Huntington's Disease
        8.4.5 Amyotrophic Lateral Sclerosis
        8.4.6 Others
    8.5 Infectious Diseases
    8.6 CNS Cancer
    8.7 Others
9. Central Nervous System Drug Delivery Market – By Drug Delivery System (Market Size -$Million/$Billion)
    9.1 Non-Invasive Methods
    9.2 Invasive Methods
10. Central Nervous System Drug Delivery Market – By Distribution Channel (Market Size -$Million/$Billion)
    10.1 Hospital Pharmacies
    10.2 Retail Pharmacies
    10.3 Others
11. Central Nervous System Drug Delivery Market - By Geography (Market Size –$Million/$Billion)
    11.1 North America
        11.1.1 U.S.
        11.1.2 Canada
        11.1.3 Mexico
    11.2 South America
        11.2.1 Brazil
        11.2.2 Venezuela
        11.2.3 Argentina
        11.2.4 Ecuador
        11.2.5 Peru
        11.2.6 Rest of South America
    11.3 Europe
        11.3.1 U.K
        11.3.2 Germany
        11.3.3 Italy
        11.3.4 France
        11.3.5 Spain
        11.3.6 Rest of Europe
    11.4 Asia Pacific
        11.4.1 China
        11.4.2 Australia
        11.4.3 Japan
        11.4.4 South Korea
        11.4.5 India
        11.4.6 Rest of Asia Pacific
    11.5 Rest of World
        11.5.1 Africa
        11.5.2 Middle East
12. Central Nervous System Drug Delivery Market - Entropy
13. Central Nervous System Drug Delivery Market – Industry/Segment Competition Landscape Premium
    13.1 Market Share Analysis
        13.1.1 Market Share by Region- Top 10 companies
        13.1.2 Market Share at Global - Top 10 companies
        13.1.3 Market Share by Countries – Top 10 Companies
        13.1.4 Competition Matrix
        13.1.5 Best Practices for Companies
14. Central Nervous System Drug Delivery Market – Key Company List by Country Premium Premium
15. Central Nervous System Drug Delivery Market Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10
"*Financials for private companies would be provided on a best efforts basis”.